scholarly journals The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

2020 ◽  
Vol 10 ◽  
Author(s):  
Wen-Fen Fu ◽  
Qing-Xia Chen ◽  
Xiao-Xiao Wang ◽  
Jie Zhang ◽  
Chuan-Gui Song
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Survival Outcomes

scholarly journals Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36480 cases. 

2020 ◽  
Author(s):  
Lin-Yu Xia ◽  
Qing-Lin Hu ◽  
Jing Zhang ◽  
Wei-Yun Xu ◽  
Xiao-Shi Li
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Current Evidence ◽  
Survival Outcomes ◽  
Significant Difference

Abstract Background: The survival outcomes of neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT) for patients with triple-negative breast cancer (TNBC) remain unclear. Therefore, in this study, a meta-analysis was conducted to analyze current evidence on the survival outcomes of NACT versus ACT in TNBC. Methods: A systematic search was performed on the PubMed and Embase databases to identify relevant articles investigating the survival outcomes of NACT versus ACT in TNBC. Results: A total of nine studies involving 36480 patients met the selection criteria. Among them,10728 (29.41%) received NACT, and 25752 (70.59%) received ACT. The pathological complete response (pCR) rate was 35% (95% CI = 0.23-0.48). Compared with ACT, the overall survival (OS) of NACT was poor (HR = 1.59; 95%CI = 1.25-2.02; P=0.0001), and there was no significant difference in disease-free survival (DFS) between the two treatments (HR = 0.85; 95%CI = 0.54-1.34; P=0.49). NACT with pCR significantly improved the OS (HR = 0.53; 95%CI = 0.29-0.98; P=0.04) and DFS (HR = 0.52; 95%CI = 0.29-0.94; P=0.03), while the OS (HR = 1.18; 95%CI = 1.09-1.28; P<0.0001) and DFS (HR = 2.36; 95%CI = 1.42-3.89; P=0.0008) of patients with residual disease (RD) following NACT were worse compared to those receiving ACT. Conclusion: These findings suggest that, for TNBC, NACT with pCR is superior to ACT in improving OS and DFS. and it turns to be opposite when patients receiving NACT with RD.

scholarly journals Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis in 36480 cases.

2020 ◽  
Author(s):  
Lin-Yu Xia ◽  
Qing-Lin Hu ◽  
Jing Zhang ◽  
Wei-Yun Xu ◽  
Xiao-Shi Li
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Current Evidence ◽  
Survival Outcomes ◽  
Significant Difference

Abstract Background The survival outcomes of neoadjuvant chemotherapy(NACT) versus adjuvant chemotherapy(ACT) in triple-negative breast cancer (TNBC) remains unclear. Therefore, in this study, a meta-analysis was conducted to analyze current evidence on the survival outcomes of neoadjuvant versus ACT in TNBC. Methods A systematic search of PubMed and Embase databases were done to identify relevant articles investigating the survival outcomes of NACT versus ACT in TNBC. Results A total of nine studies involving 36480 patients met the selection criteria.Of them,10728(29.41%) received NACT, and 25752(70.59%) received ACT.The pathological complete response (pCR) rate is 35% (95% CI = 0.23-0.48). Compared with ACT, the overall survival(OS) of NACT was poor(HR = 1.59; 95%CI = 1.25-2.02; P=0.0001), and there was no significant difference in disease-free survival(DFS) between them(HR = 0.85; 95%CI = 0.54-1.34; P=0.49). NACT with pCR can significantly improve the OS(HR = 0.53; 95%CI = 0.29-0.98; P=0.04) and DFS(HR = 0.52; 95%CI = 0.29-0.94; P=0.03), while the OS(HR = 1.18; 95%CI = 1.09-1.28; P<0.0001) and DFS(HR = 2.36; 95%CI = 1.42-3.89; P=0.0008) of patients with residual disease(RD) following NACT were worse compared with ACT. Conclusion The findings suggest that, for TNBC, Patients receiving NACT with pCR can significantly improve OS and DFS compared with ACT and it turns to be opposite when patients receiving NACT with RD.

scholarly journals MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer

Oncogene ◽  
2021 ◽  
Author(s):  
Jhih-Kai Pan ◽  
Cheng-Han Lin ◽  
Yao-Lung Kuo ◽  
Luo-Ping Ger ◽  
Hui-Chuan Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Survival Outcomes ◽  
Poor Survival ◽  
Breast Cancer Brain Metastasis ◽  
High Level

AbstractBrian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood–brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis.

PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 541-541
Author(s):  
Xue Wang ◽  
Peng Yuan ◽  
Feng Du ◽  
Lina Cui ◽  
Fangchao Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Genetic Alterations ◽  
Functional Enrichment ◽  
Pathway Enrichment Analysis ◽  
Genetic Characteristics ◽  
Significant Difference

541 Background: Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that is markedly heterogeneous and lacks specific targets. The aim of this study is to explore potential predictors and therapeutic targets based on clinical and genetic characteristics. Methods: 138 patients with triple-negative breast cancer after surgical treatment were 1:1 randomly assigned to the paclitaxel combined with carboplatin (TCb) group or the epirubicin combined with cyclophosphamide sequential paclitaxel (EC-T) adjuvant chemotherapy group. PD-L1 was retrospectively analyzed by surgically resected specimens, and 733 cancer-related genes were detected by NGS. Pathway enrichment analysis was performed using DAVID for functional enrichment genetic alterations. Cox regression models and Kaplan-Meier were used to evaluate disease-free survival (DFS). Results: In this study, there was no significant difference in DFS between the TCb and EC-T groups. 31 (22.5%) of 138 TNBC patients were positive for PD-L1 expression, including 15 (10.9%) patients positive for PD-L1 in tumor cells (TCs) and 29 (21.0%) patients positive for PD-L1 in tumor-infiltrating immune cells (TICs). Patients with positive PD-L1 expression, either in TCs or TICs, achieved better DFS [HR=0.13 (95% CI: 0.02-0.93), p=0.016], the difference was also shown in the EC-T group [HR=0 (95% CI: 0- inf), p=0.037], but not in the TCb group [HR=0 (95% CI: 0.04-2.1), p=0.189]. In addition, we identified 7 patients with mutations in DNA topoisomerase IIIα(TOP3A), a homologous recombination (HR)-related gene, and patients with mutations in this gene had worse DFS than those without mutations [HR=4]. However, there was no statistically significant association between BRCA mutation and response to either therapeutic regimens. Conclusions: In this TNBC patient population, immunohistochemistry (IHC) and NGS analyses identified potential prognostic markers. PD-L1 positive and TOP3A mutation were significantly associated with early triple-negative breast cancer prognosis.

Sign in / Sign up

Export Citation Format

Share Document